Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04665687
Other study ID # 2020-08-070-002
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date December 17, 2020
Est. completion date December 31, 2022

Study information

Verified date September 2020
Source Samsung Medical Center
Contact Hyuk Lee, Professor
Phone +8210-3736-1787
Email leehyuk@skku.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Because advanced gastric cancer shows poor prognosis, it is important to detect early gastric cancer or precancerous gastric adenoma patients who have a cure rate of 95% or more. Moreover, a large part of early gastric cancer can be completely resected by endoscopic resection, thus ensuring a very high quality of life for patients. However, there are currently no markers that can be used for diagnosis of early gastric cancer or gastric adenoma. In addition, the biggest problem after endoscopic resection of early gastric cancer is metachronous recurrence of the cancer, which requires repeated endoscopic resection or additional surgical gastrectomy. However, there are no discovered markers for prediction of recurrence. Liquid biopsy is a method of obtaining body fluids such as gastric juice or effusion through an endoscopic inlet during gastroscopy or colonoscopy and blood. Based on the advanced analysis method, liquid biopsy reveals more genetic information than tissue biopsy. Therefore, it is highly likely to become an essential factor in future personalized medicine. Therefore, this study was designed to identify whether tumor's molercular profiling based on tissue or blood could be used for prediction of prognosis and diagnosis of early gastric cancer and precancerous gastric adenoma.


Description:

1. Acquisition of tumor samples : Tissue and 10ml of blood will be collected for genomic examination of those histologically diagnosed with early gastric cancer or precancerous gastric adenoma lesion, and additional tissue and blood will be collected at 2 months, 1 year after treatment, and recurrence. 2. Suitability of tmor samples : Tumor areas (> 60%) are dissected under microscopy from 4-μm-thick unstained sections by comparison with an H&E stained slide, and genomic DNA was extracted using a Qiagen DNA FFPE Tissue Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. After extraction, we measured concentrations and 260/280 and 260/230 nm ratios using a spectrophotometer (ND1000, Nanodrop Technologies, ThermoFisher Scientific, MA, USA). Each sample was then quantified with an Qubit fluorometer (Life Technologies, Carlsbad, CA, USA). Samples of genomic DNA with more than 10 ng measured by the Qubit fluorometer were subjected to AmpliSeq library preparation. To identify "druggable" CNVs, we used a 21-gene nCounter CNV assay. 3. Method of tumor molecular profiling - Ion Torrent PGM Amplieq Cancer Panel 2.0 : We use the Ion AmpliSep Cancer Panel V2(Ion Torrent) to detect frequent somatic mutations that were selected based on literature review. It examines 285 mutations in 50 commonly mutated oncogenes and tumor supressor genes. First, 10ng of DNA from each 89 FFPE tumor samples underwent single-tube, multiplex PCR amplication using the Ion AmpliSepCancer Primer Pool and the AmpliSepKit reagents (Life Technologies).Treatment of the resulting amplicons with FuPa Preagent partially digest the primers and phosphorylate the amplicons. The phosphorylate the amplicons are ligated to Ion dapters and purfied. For barcoded library preparation, we substitite barcoded adapters from the Ion XpressTM Library Kit. The ligated DNA undergose nick translation and amplication to complete the linkage between adapters and amplicons and to generate sufficient material for dowmstream template treparation. Two rounds of Agencourt® AMPure® XP Reagent binding at 0.6 and 1.2 bead- to- sample volum ratios removed input DNA and unincorporated primers form the amplicons. The final library molecules are 125-300bp in size. We then transfer the libries to the Ion OneTouchTM system for automated template preparation. Sequencing is performed on the Ion PGMTM sequencer according to the manufacturer's instructions. We use IonTorrent Software for automated data analysis. - nCounter copy Number Variation CodeSets : We custom designed a 21-gene CNV assay as outlined in a previous study. The 21 genes included AURAKA, CCND1, CCNE1, CDK4, CDK6, CDNK1A, CDNK2A, EGFR, ERBB2, ERBB3, FGFR1, FGFR2, IGFR1R, KLF5, KRAS, MDM2, MET, MITF, MYC, PIK3CA, and TNIK. For detection of CNVs, nCounter Copy Number Variation CodeSets were used with 200 ng purified genomic DNA. DNA was fragmented via AluI digestion and denatured at 95°C. Fragmented DNA was hybridized with the codeset of 21 genes in the nCounter Cancer CN Assay Kit (Nanostring Technologies) for 18 h at 65°C and processed according to the manufacturer's instructions. The nCounter Digital Analyzer counted and tabulated the signals of reporter probes. Quantified data were analyzed using NanoString's nSolver Analysis Software. - Immunohistochemistry : RET, ATM, PD-L1, FGFR2, MLH, EGFR, ALK, ROS, TRKA. MET, HER2, PTEN loss (EGFR,CCNEI in selected cases) - Cancer Scan : targeted deep sequencing at Samsung Genome Institute : Illumina HiSeq2000/2500-based, MiSeq NGS targeted sequencing - ASFA™ Spotter 4. Statistics : Analysis of genetic research is primarily technical. Data are presented using summary statistics tables and graphs. The total disease-free survival period is calculated by the Kaplan-Meier method through medical records of subjects who have undergone endoscopic resection.


Recruitment information / eligibility

Status Recruiting
Enrollment 1730
Est. completion date December 31, 2022
Est. primary completion date December 31, 2022
Accepts healthy volunteers
Gender All
Age group 19 Years to 100 Years
Eligibility Inclusion Criteria: 1. Those who are over the age of 19 2. Those who were histologically confirmed with early gastric cancer or precancerous gastric adenoma 3. Patients with early gastric cancer or precancerous gastric adenoma falling under the above criteria who have excess tissue stored from previous non-research purpose biopsy/endodoscopic removal for treatment and diagnosis 4. Those whose life expectancy is more than 3 months 5. Those who have voluntarily consented to participate in this clinical trial Exclusion Criteria: 1. Those who will not yield enough samples 2. Those who are considered inappropriate for this study in the discretion of the researchers

Study Design


Locations

Country Name City State
Korea, Republic of Samsung medical center Seoul

Sponsors (1)

Lead Sponsor Collaborator
Samsung Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Identify biomarkers for differential diagnosis between early gastric cancer and precancerous adenoma. Tumor's moleular profiling is assessed by following method:
Ion Torrent PGM Amplieq Canccer Panel 2.0
Nanostring copy number variation (CNV) panel
Immunohistochemistry: RET, ATM, PD-L1, FGFR2, MLH, EGFR, ALK, ROS, TRKA. MET, HER2, PTEN loss (EGFR,CCNEI in selected cases)
Illumina HiSeq2000/2500-based, MiSeq NGS targeted sequencing
ASFA™ Spotter
From the date of initial treatment until the date of first recurrence or up to 2 years, whichever came first.
Primary Indentify prognostic biomarkers for predicting recurrence of early gastric cancer and precancerous adenoma lesion. Comparison of tumor's molecular profile between the cases of recurrence and non-recurrence.
Tumor's moleular profiling is assessed by following method:
Ion Torrent PGM Amplieq Canccer Panel 2.0
Nanostring copy number variation (CNV) panel
Immunohistochemistry: RET, ATM, PD-L1, FGFR2, MLH, EGFR, ALK, ROS, TRKA. MET, HER2, PTEN loss (EGFR,CCNEI in selected cases)
Illumina HiSeq2000/2500-based, MiSeq NGS targeted sequencing
ASFA™ Spotter
From the date of initial treatment until the date of first recurrence or up to 2 years, whichever came first.
Secondary Change in the tumor's molecular profile on serial biopsies at the time of initial treatment, 2 months after treatment, 1 year after treatment, or recurrence. The method of tumor's moleular profiling is same as the above. From the date of initial treatment until the date of first recurrence or up to 2 years, whichever came first.
See also
  Status Clinical Trial Phase
Terminated NCT04977401 - EndoscoPic Submucosal dIssection Using geL Versus glycerOl for Submucosal iNjection N/A
Not yet recruiting NCT04083573 - Comparison of Diagnostic Performance of Medical Monitor and Medical Augmented Reality Glasses in Endoscopy: Observation Study
Completed NCT02504164 - Effect of Midazolam Premedication on the Satisfaction Levels of Patients After Endoscopic Submucosal Dissection N/A
Recruiting NCT01774266 - Detection of Methylated Reprimo in Plasma for Asymptomatic Gastric Cancer N/A
Completed NCT01435525 - Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation N/A
Completed NCT01921283 - Monitored Anesthesia Care With Propofol Plus Remifentanil During Endoscopic Submucosal Dissection: Evaluation of Bispectral Index Monitoring N/A
Completed NCT01364324 - Pharmacokinetics of Anti-tuberculosis Drugs in Gastrectomized Patients
Recruiting NCT03837301 - Non-exposure Simple Suturing EFTR (NESS-EFTR) With Laparoscopic Sentinel Lymph Node Navigation for EGC (Senorita3-phase 2) Phase 2
Recruiting NCT05269056 - Early Detection of Gastric Cancer Using Plasma Cell-free DNA Fragmentomics
Not yet recruiting NCT03632746 - Verifying the Specificity of a New Method in Predicting Lymph Node Metastasis in Early Gastric Cancer Patients
Completed NCT01938326 - Pure Single Incision Laparoscopic Distal Gastrectomy (SIDG) Versus Totally Laparoscopic Distal Gastrectomy (TLDG) N/A
Recruiting NCT04602689 - Fibrin Glue After ESD for High Risk Patients of Bleeding N/A
Recruiting NCT05291728 - Screening for Early Gastric Cancer in Shaanxi Province
Not yet recruiting NCT06152783 - Confocal Laser Microendoscopy (CellTouch) for the Diagnosis of Early Gastric Cancer: A Multicenter Clinical Study
Completed NCT02189226 - Usefulness of Probe-based Confocal Laser Endo-microscopy in Delineation of Margin of Early Gastric Cancer for Endoscopic Submucosal Dissection N/A
Completed NCT04602299 - Setting the Shortest Examination Time of Gastroscopy to Improve the Detection Rate of Upper Gastrointestinal Tumors N/A
Completed NCT02562976 - OLGA Stage is More Appropriate in Predicting Early Gastric Cancer N/A
Recruiting NCT01132469 - Efficacy and Safety Study of Endoscopic Submucosal Dissection for Early Gastric Cancer N/A
Completed NCT03136354 - Prospective Randomized Trial Comparing Endoscopic Submucosal Dissection Against Laparoscopic Assisted Gastrectomy for Treatment of Early Gastric Cancer N/A
Completed NCT02216110 - Endoscopic Submucosal Dissection Versus Gastrectomy N/A